Can Nano Yield Big Insights? Oligonucleotide-Based Biosensors in Early Diagnosis of Gastric Cancer

Abstract

Gastric cancer (GC) remains a significant global health challenge, with late-stage diagnosis impacting treatment options and decreased survival rates. To address this, there has been a growing interest in the development of innovative screening and diagnostic methods. Over the past 20 years, nanobiosensors have undergone multiple iterations and unveiled remarkable features that pledge to reshape patient care. Despite the excitement over the plethora of ground-breaking advancements for cancer detection, use-ready samples and streamlined healthcare information monitoring and usage, this technology is still awaiting entry into clinical trials, urging a closer gaze within the medical community. Oligonucleotide-based biosensors, leveraging DNA or RNA’s long-term storage of information, offer great specificity and sensitivity, as described throughout this paper. Consequently, this renders them as an ideal choice for revolutionizing GC diagnosis and facilitating early intervention. The aim of this review is to provide an overview of this cutting-edge, invaluable technology and its limitations across various aspects.

Keywords

• biosensors
• nanotechnology
• DNA
• RNA
• point-of-care testing
• early cancer detection